Lista de obras - Judit Morello - Dominio Público Uruguay

A Metabolomics-Inspired Strategy for the Identification of Protein Covalent Modifications

scientific article published on 31 July 2019

Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients

artículo científico publicado en 2011

Association between tipranavir plasma levels and virological response in HIV-infected patients

artículo científico publicado en 2008

Differences in lopinavir plasma concentrations comparing Kaletra film coated tablets and soft gelatine capsules that result in various lipid abnormalities.

artículo científico publicado en 2009

Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.

artículo científico publicado en 2008

Drug interactions of tipranavir, a new HIV protease inhibitor

artículo científico publicado en 2007

Effect of Suboptimal Sampling and Handling Conditions on Urinary Metabolic Profiles

article by Judit Morello et al published 19 October 2014 in Chromatographia

Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial

artículo científico publicado en 2007

Exploratory metabolomics study of the experimental opisthorchiasis in a laboratory animal model (golden hamster, Mesocricetus auratus).

artículo científico publicado en 2017

Impact of inosine triphosphatase gene variants on the risk of anemia in HIV/hepatitis C virus-coinfected patients treated for chronic hepatitis C.

artículo científico publicado en 2011

Implications of sulfotransferase activity in interindividual variability in drug response: clinical perspective on current knowledge.

artículo científico publicado en 2017

Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin

artículo científico publicado en 2008

Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection

artículo científico publicado en 2010

Mass Spectrometry-Based Methodologies for Targeted and Untargeted Identification of Protein Covalent Adducts (Adductomics): Current Status and Challenges

artículo científico publicado en 2019

Measurement of ribavirin plasma concentrations by high-performance liquid chromatography using a novel solid-phase extraction method in patients treated for chronic hepatitis C.

artículo científico publicado en 2007

Mercapturate Pathway in the Tubulocentric Perspective of Diabetic Kidney Disease

scientific article published on 09 January 2019

Monitoring of the lactonase activity of paraoxonase-1 enzyme in HIV-1-infection.

artículo científico publicado en 2014

Noncirrhotic portal hypertension in HIV infection

artículo científico publicado en 2011

Plasma raltegravir exposure influences the antiviral activity and selection of resistance mutations.

artículo científico publicado en 2011

Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study

artículo científico publicado en 2009

Preemptive erythropoietin plus high ribavirin doses to increase rapid virological responses in HIV patients treated for chronic hepatitis C.

artículo científico publicado en 2010

Raltegravir and etravirine are active against HIV type 1 group O.

artículo científico publicado en 2009

Rate and predictors of success in the retreatment of chronic hepatitis C virus in HIV/hepatitis C Virus coinfected patients with prior nonresponse or relapse

artículo científico publicado en 2010

Role of atazanavir in the treatment of HIV infection

artículo científico publicado en 2009

Safety and efficacy of tenofovir/emtricitabine plus nevirapine in HIV-infected patients

artículo científico publicado en 2010

Severe Acute Kidney Injury and Double Tubulopathy Due to Dual Toxicity Caused by Combination Antiretroviral Therapy.

artículo científico publicado en 2018

Short Communication: Use of Serum Bilirubin Levels as Surrogate Marker of Early Virological Response to Atazanavir-Based Antiretroviral Therapy

scientific article published on 23 March 2011

Simplification from protease inhibitors to once- or twice-daily raltegravir: the ODIS trial

artículo científico publicado en 2010

Sustained virological response in HIV/HCV co-infected patients without rapid virological response (RVR) on peginterferon-ribavirin therapy.

artículo científico publicado en 2010

Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring

artículo científico publicado en 2008

The benefit of simplification from tipranavir/ritonavir 500/200 bid to 500/100 bid guided by therapeutic drug monitoring

artículo científico publicado en 2010

The first-line antiepileptic drug carbamazepine: Reaction with biologically relevant free radicals

article

The mercapturomic profile of health and non-communicable diseases

artículo científico publicado en 2019

Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients

article

Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements

artículo científico publicado en 2008

Use of different inhibitory quotients to predict early virological response to tipranavir in antiretroviral-experienced human immunodeficiency virus-infected patients.

artículo científico publicado en 2009

Use of the HCP5 single nucleotide polymorphism to predict hypersensitivity reactions to abacavir: correlation with HLA-B*5701.

artículo científico publicado en 2010

Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C.

scientific article published on 17 October 2008

Usefulness of zebrafish larvae to evaluate drug-induced functional and morphological renal tubular alterations

artículo científico publicado en 2017

Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes

artículo científico publicado en 2011

Zebrafish Larvae Are a Suitable Model to Investigate the Metabolic Phenotype of Drug-Induced Renal Tubular Injury

artículo científico publicado en 2018

Lista de obras de Judit Morello

A Metabolomics-Inspired Strategy for the Identification of Protein Covalent Modifications

Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients

Association between tipranavir plasma levels and virological response in HIV-infected patients

Differences in lopinavir plasma concentrations comparing Kaletra film coated tablets and soft gelatine capsules that result in various lipid abnormalities.

Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.

Drug interactions of tipranavir, a new HIV protease inhibitor

Effect of Suboptimal Sampling and Handling Conditions on Urinary Metabolic Profiles

Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial

Exploratory metabolomics study of the experimental opisthorchiasis in a laboratory animal model (golden hamster, Mesocricetus auratus).

Impact of inosine triphosphatase gene variants on the risk of anemia in HIV/hepatitis C virus-coinfected patients treated for chronic hepatitis C.

Implications of sulfotransferase activity in interindividual variability in drug response: clinical perspective on current knowledge.

Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin

Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection

Mass Spectrometry-Based Methodologies for Targeted and Untargeted Identification of Protein Covalent Adducts (Adductomics): Current Status and Challenges

Measurement of ribavirin plasma concentrations by high-performance liquid chromatography using a novel solid-phase extraction method in patients treated for chronic hepatitis C.

Mercapturate Pathway in the Tubulocentric Perspective of Diabetic Kidney Disease

Monitoring of the lactonase activity of paraoxonase-1 enzyme in HIV-1-infection.

Noncirrhotic portal hypertension in HIV infection

Plasma raltegravir exposure influences the antiviral activity and selection of resistance mutations.

Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study

Preemptive erythropoietin plus high ribavirin doses to increase rapid virological responses in HIV patients treated for chronic hepatitis C.

Raltegravir and etravirine are active against HIV type 1 group O.

Rate and predictors of success in the retreatment of chronic hepatitis C virus in HIV/hepatitis C Virus coinfected patients with prior nonresponse or relapse

Role of atazanavir in the treatment of HIV infection

Safety and efficacy of tenofovir/emtricitabine plus nevirapine in HIV-infected patients

Severe Acute Kidney Injury and Double Tubulopathy Due to Dual Toxicity Caused by Combination Antiretroviral Therapy.

Short Communication: Use of Serum Bilirubin Levels as Surrogate Marker of Early Virological Response to Atazanavir-Based Antiretroviral Therapy

Simplification from protease inhibitors to once- or twice-daily raltegravir: the ODIS trial

Sustained virological response in HIV/HCV co-infected patients without rapid virological response (RVR) on peginterferon-ribavirin therapy.

Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring

The benefit of simplification from tipranavir/ritonavir 500/200 bid to 500/100 bid guided by therapeutic drug monitoring

The first-line antiepileptic drug carbamazepine: Reaction with biologically relevant free radicals

The mercapturomic profile of health and non-communicable diseases

Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients

Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements

Use of different inhibitory quotients to predict early virological response to tipranavir in antiretroviral-experienced human immunodeficiency virus-infected patients.

Use of the HCP5 single nucleotide polymorphism to predict hypersensitivity reactions to abacavir: correlation with HLA-B*5701.

Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C.

Usefulness of zebrafish larvae to evaluate drug-induced functional and morphological renal tubular alterations

Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes

Zebrafish Larvae Are a Suitable Model to Investigate the Metabolic Phenotype of Drug-Induced Renal Tubular Injury